GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.
Britain’s biggest drugmaker poached Miels in January in the first major appointment by incoming GSK Chief Executive Emma Walmsley. But his arrival was stalled by an AstraZeneca lawsuit disputing when he could join.
GSK said on Monday it had now struck an agreement with AstraZeneca for Miels to start on Sept. 4, avoiding the need for a court case over his contract.
Miels had headed AstraZeneca’s European business and his defection was a blow to the company, which has seen a number of senior management departures.
For Walmsley, his appointment is viewed as pivotal, since he will be a key lieutenant as she tries to steer GSK’s core pharmaceuticals business towards improved productivity and higher profits.
Originally, GSK had hoped for a lengthy handover period during which Miels would work alongside outgoing pharma head Abbas Hussain. However, the delay in his arrival means this will not now be possible.
Miels, who has both commercial and scientific experience after working at AstraZeneca, Roche and Sanofi, will arrive as GSK is looking to a new wave of drugs to offset the decline of lung treatment Advair.
Walmsley, who became GSK CEO on April 1, worked in marketing and management at L’Oreal for 17 years before joining the drugmaker and has her roots a long way from the pharmaceutical lab bench.
That has raised doubts among some investors about her insight into prescription drugs and she is expected to rely heavily on advice from Miels, as well as GSK’s research boss Patrick Vallance.
By Ben Hirschler
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.